Valuation: ABVC BioPharma, Inc.

Market Cap 25.96M 23.25M 21.39M 19.38M 36.23M 2.47B 36.9M 255M 102M 1.3B 97.44M 95.37M 4.09B P/E 2024
-1.4x
P/E 2025 -5.42x
Enterprise Value 28.69M 25.7M 23.64M 21.42M 40.03M 2.72B 40.78M 282M 113M 1.43B 108M 105M 4.52B EV / Sales 2024
19.8x
EV / Sales 2025 -
Free-Float
79.73%
Yield 2024 *
-
Yield 2025 -
1 day-3.85%
1 week-3.85%
Current month-5.66%
1 month-5.66%
3 months-7.41%
6 months-2.91%
Current year-53.05%
1 week 1
Extreme 1
1.11
1 month 0.89
Extreme 0.8918
1.11
Current year 0.71
Extreme 0.7069
2.43
1 year 0.71
Extreme 0.7069
3.06
3 years 0.4
Extreme 0.4
5.48
5 years 0.4
Extreme 0.4
116.9
10 years 0.4
Extreme 0.4
378
Manager TitleAgeSince
Chief Executive Officer 40 21/06/2023
Chief Tech/Sci/R&D Officer 72 15/06/2023
Director TitleAgeSince
Chairman 39 01/07/2015
Director/Board Member 65 23/11/2017
Director/Board Member 55 23/11/2017
Date Insider Type Main position Quantity % Market Cap. Importance
20/5/22 Other

Chairman

7,908,805 26.0954%
2/8/21 Other

Director

5,949 0.0243%
2/8/21 Other

Chief Executive Officer

18,404 0.0752%
Change 5-day change 1-year change 3-year change Capi.($)
-3.85%-3.85%-64.54%-17.36% 25.96M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average -0.08%+6.40%+36.62%+183.95% 39.44B
Weighted average by Cap. +0.18%+5.44%+48.49%+186.12%

Financials

2024 2025
Net sales 510K 456K 420K 380K 711K 48.39M 724K 5.01M 2.01M 25.45M 1.91M 1.87M 80.27M -
Net income -4.9M -4.39M -4.04M -3.66M -6.84M -466M -6.97M -48.17M -19.34M -245M -18.4M -18.01M -772M -7.91M -7.08M -6.52M -5.9M -11.03M -751M -11.24M -77.69M -31.19M -395M -29.68M -29.05M -1.25B
Net Debt 2.88M 2.58M 2.37M 2.15M 4.02M 274M 4.1M 28.31M 11.37M 144M 10.82M 10.59M 454M 2.73M 2.44M 2.25M 2.04M 3.81M 259M 3.88M 26.79M 10.76M 136M 10.24M 10.02M 430M
Projected Income Statement - Annual - ABVC BioPharma, Inc.
Logo ABVC BioPharma, Inc.
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Employees
-
Date Price Change Volume
30/10/26 USD 1.000 -3.85% 20,203
29/10/26 USD 1.040 -4.59% 34,879
28/10/26 USD 1.090 +3.81% 35,408
27/10/26 USD 1.050 0.00% 24,225
26/10/26 USD 1.050 +0.96% 36,596
  1. Stock Market
  2. Stocks
  3. ABVC Stock